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Cellular and Molecular
Modulation and Lack of Cross-Talk between
Signal Transducer and Activator of
Transcription 5 and Suppressor of Cytokine
Signaling-3 in Insulin and Growth Hormone
Signaling in 3T3-L1 Adipocytes
David J. Story and Jacqueline M. Stephens
Abstract
STORY, DAVID J. AND JACQUELINE M. STEPHENS.
Modulation and lack of cross-talk between signal transducer
and activator of transcription 5 and suppressor of cytokine
signaling-3 in insulin and growth hormone signaling in
3T3-L1 adipocytes. Obesity. 2006;14:1303–1311.
Objective: To examine the role of signal transducer and
activator of transcription (STAT) 5 and suppressor of cyto-
kine signaling (SOCS)-3 in the cross-talk between growth
hormone and insulin (INS) signaling in fat cells.
Research Methods and Procedures: Fully differentiated
3T3-L1 adipocytes were exposed to INS, growth hormone
(GH), or both of these growth factors, and the activation of
STAT5 proteins and mitogen-activated protein kinase was
examined using phospho-specific antibodies. The induction
of SOCS-3 mRNA was assessed by Northern blot analysis.
INS-stimulated glucose transport was also measured.
Results: We observed that GH, not INS, induced STAT5
activation in adipocytes in a manner that was independent of
extracellular signal-regulated kinase (ERK) activation or
new protein synthesis. GH strongly induced SOCS-3
mRNA expression, whereas INS had a much less potent
effect on SOCS-3 mRNA expression. Because SOCS-3 has
been implicated in the attenuation of GH and INS signaling,
we examined the cross-talk between these signaling path-
ways. GH pretreatment of adipocytes inhibited GH signal-
ing. Similarly, INS pretreatment inhibited INS signaling.
However, INS did not block the GH-induced activation of
STAT5, and GH did not block the INS induction of ERK
activity or of increased glucose uptake. We observed that
neither new protein synthesis nor activation of ERKs 1 and
2 were required for the inhibition of GH signaling.
Discussion: These results demonstrate that blocking the
induction of the SOCS-3 protein has no effect on the atten-
uation of GH signaling and support recent studies suggest-
ing that SOCS proteins have additional functions. In addi-
tion, these studies demonstrate that GH-induced SOCS-3
expression is insufficient to inhibit INS-induced glucose
uptake in adipocytes.
Key words: signal transducer and activator of transcrip-
tion-5, suppressor of cytokine signaling-3, adipocytes,
extracellular signal-regulated kinases 1 and 2, mitogen-
activated protein kinase
Introduction
Insulin (INS)1 action involves a complex network of
signaling pathways that are activated by the INS receptor
and regulate intermediary metabolism in many cells (1).
Although the effects of INS on glucose and lipid metabo-
lism are well documented, numerous gaps remain in our
understanding of the precise molecular mechanisms of sig-
nal transduction. Moreover, recent studies have shown thatReceived for review September 22, 2004.
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many other hormones and signaling events have the ability
to attenuate or enhance INS action.
Signal transducer and activator of transcription (STAT)
is a family of transcription factors that is comprised of
seven family members (STATs 1, 2, 3, 4, 5A, 5B, and 6).
In response to stimulation of various receptors, mainly
those for cytokines, STATs are tyrosine phosphorylated and
translocate to the nucleus. Each STAT family member
shows a distinct pattern of activation by cytokines and on
nuclear translocation can regulate the transcription of par-
ticular genes in cell- or tissue-specific manners (2). Sup-
pressor of cytokine signaling (SOCS) is a family of eight
proteins (cytokine inducible SH2 protein and SOCSs 1 to 7)
that are also induced by many cytokines and have been to
shown to be involved in the attenuation of Janus tyrosine
kinase (JAK)-STAT signaling (for review, see 3).
STAT5 proteins have been shown to be activated by
growth hormone (GH) in many cell types. However, some
recent studies also suggest that STAT5B is a physiological
substrate of the INS receptor in a variety of cells types
(4–6). Two of these studies suggest that INS activation of
STAT5B is independent of JAK2 kinase, which is normally
involved in STAT5 phosphorylation. Similar findings have
been reported for SOCS-3. One study has demonstrated
that SOCS-3 mRNA and STAT5B phosphorylation are in-
duced by INS in 3T3-L1 adipocytes (7). These studies by
Emanuelli et al. (7) suggest that SOCS-3 and STAT5B
compete for binding at phosphotyrosine residue 960 of the
INS receptor. Moreover, SOCS-3 expression appears to
inhibit INS signaling and is up regulated in fat tissue of
obese mice. Additional studies by this group also suggest
that INS phosphorylates SOCS-3 by JAK kinases (8). Ec-
topically expressed SOCS-3 has been shown to associate
with the INS receptor and suppress INS-dependent receptor
autophosphorylation, INS receptor substrate (IRS)-1 ty-
rosine phosphorylation, association of IRS-1 with the p85
subunit of phosphatidylinositol 3-kinase, and activation of
Akt in hepatocytes (9). SOCS-3 was also shown to be a
direct inhibitor of INS receptor autophosphorylation in vitro
(9). Inhibition of SOCS-3 in obese diabetic mice has been
shown to improve INS sensitivity (10), and decreased INS
signaling has been observed in SOCS-3-deficient adipo-
cytes (11). Transgenic mice with elevated SOCS-3 in adi-
pose tissue (aP2-SOCS-3 mice) have decreased IRS-1 levels
and impaired INS signaling (12). SOCS-3 is also activated
by resistin and plays a role in its ability to attenuate INS
signaling (13). SOCS-1 and -6 have also been shown to
associate with the INS receptor and act as potential inhibi-
tors of INS receptor signaling in rat hepatoma cells (14).
In the past few years, we have focused on the activation
of STAT proteins in cultured and rodent adipocytes. Our
results demonstrate highly restricted activation of STAT5
proteins in fat cells. Of more than 25 cytokines and growth
factors examined, only GH treatment resulted in the activa-
tion of STATs 5A and 5B in cultured and rodent adipocytes
(15). GH signaling is known to be initiated by the binding
of a single GH molecule to a pair of GH receptors. The
dimerization of these receptors leads to the activation of
JAK2, a cytosolic tyrosine kinase that associates with the
cytoplasmic domain of the receptor and is thought to mod-
ulate all of the downstream signaling events from these
receptors (16). The signaling molecules that are recruited
and activated by the GH receptor-JAK2 complex include
STATs, the adapter protein Shc, and the IRSs 1 and 2. The
recruitment and activation of these signaling intermediates
leads to the activation of enzymes such as mitogen-activated
protein kinase (MAPK), phosphatidylinositol-3-kinase,
protein kinase C, and phospholipase A2 and to the release of
various second messengers such as diacylglycerol, calcium,
and nitric oxide. Clearly, there appears to be many similar-
ities in the GH and INS signaling cascades. Moreover, the
functional interactions between GH and INS are complex
and poorly understood, particularly in adipocytes.
The goal of this project was to compare the effects of GH
and INS on STAT5 phosphorylation and the induction of
SOCS-3 mRNA in adipocytes. In addition, we examined the
cross-talk between these two signaling pathways in 3T3-L1
adipocytes. As expected, GH was a potent inducer of
STATs 5A and 5B. However, a variety of INS treatments
had no effect on STAT5 activation. Interestingly, both GH
and INS were capable of inducing SOCS-3 mRNA in an
extracellular signal-regulated kinase (ERK) 1- and 2-inde-
pendent manner. Yet, INS was a weak inducer of SOCS-3
mRNA, when compared with GH, and did not result in
detectable levels of SOCS-3 protein. Also, the weak induc-
tion of SOCS-3 by INS was insufficient to attenuate GH
action. Our studies on GH action revealed that GH, but not
INS, preincubation could inhibit acute GH signaling. More-
over, the inhibition of GH signaling did not require new
protein synthesis, in particular the translation of SOCS-3
mRNA. Also, the GH-mediated induction of SOCS-3 did
not attenuate INS signaling as judged by INS-stimulated
glucose uptake. In summary, our results are distinct from
other recent studies, and our findings demonstrate that the
induction of SOCS-3 is not required for the attenuation of
GH or INS signaling in 3T3-L1 adipocytes.
Research Methods and Procedures
Materials
Dulbecco’s modified Eagle’s medium (DMEM) was pur-
chased from Invitrogen (Carlsbad, CA). Bovine and fetal
bovine sera were obtained from Sigma (St. Louis, MO) and
Invitrogen, respectively. GH and INS were purchased from
Sigma. The non-phospho-STAT antibodies were monoclo-
nal IgGs purchased from BD Biosciences Transduction
Laboratories (Lexington, KY) or polyclonal IgGs from
Santa Cruz Biochemicals (Santa Cruz, CA). A highly phos-
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pho-specific polyclonal antibody for STAT5 (Y694) was
purchased from Upstate Biotechnology (Lake Placid, NY).
ERK1/ERK2 was a rabbit polyclonal from Santa Cruz Bio-
chemicals. An anti-active MAPK (ERK1/2) polyclonal and
the UO126 were obtained from Promega (Madison, WI).
Cell Culture
Murine 3T3-L1 preadipocytes were plated and grown to
2 days post-confluence in DMEM with 10% bovine serum.
Medium was changed every 48 hours. Cells were induced
to differentiate by changing the medium to DMEM contain-
ing 10% fetal bovine serum, 0.5 mM 3-isobutyl-1-methyl-
xanthine, 1 M dexamethasone, and 1.7 M INS. After 48
hours, this medium was replaced with DMEM supple-
mented with 10% fetal bovine serum, and cells were main-
tained in this medium until utilized for experimentation.
Preparation of Whole-Cell Extracts
Monolayers of 3T3-L1 adipocytes were rinsed with phos-
phate-buffered saline and then harvested in a non-denatur-
ing buffer containing 150 mM NaCl, 10 mM Tris (pH 7.4),
1 mM EGTA, 1 mM EDTA, 1% Triton-X 100, 0.5% Non-
idet P-40, 1 M phenylmethanesulfonyl fluoride, 1 M
pepstatin, 50 trypsin inhibitory mU of aprotinin, 10 M
leupeptin, and 2 mM sodium vanadate. Samples were ex-
tracted for 30 minutes on ice and centrifuged at 15,000 rpm
at 4 °C for 15 minutes. Supernatants containing whole-cell
extracts were analyzed for protein content using a bicincho-
ninic acid kit (Pierce Chemical, Rockford, IL) according to
the manufacturer’s instructions.
Preparation of Nuclear/Cytosolic Extracts
Cell monolayers were rinsed with phosphate-buffered
saline and then harvested in a nuclear homogenization
buffer (NHB) containing 20 mM Tris (pH 7.4), 10 mM
NaCl, and 3 mM MgCl2. Nonidet P-40 was added to a final
concentration of 0.15%, and cells were homogenized with
16 strokes in a Dounce homogenizer. The homogenates
were centrifuged at 1500 rpm for 5 minutes. Supernatants
were saved as cytosolic extract, and the nuclear pellets were
resuspended in 0.5 volumes of NHB and were centrifuged
as before. The pellet of intact nuclei was resuspended again
in 0.5 of the original volume of NHB and centrifuged again.
A small portion of the nuclei was used for Trypan Blue
staining to examine the integrity of the nuclei. The majority
of the pellet (intact nuclei) was resuspended in an extraction
buffer containing 20 mM HEPES (pH 7.9), 420 mM NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, and 25% glycerol. Nuclei
were extracted for 30 minutes on ice and then placed at
room temperature for 10 minutes. Two hundred units of
DNase1 were added to each sample, and tubes were inverted
and incubated an additional 10 minutes at room tempera-
ture. Finally, the sample was subjected to centrifugation at
15,000 rpm at 4 °C for 30 minutes. Supernatants containing
nuclear extracts were analyzed for protein content.
Gel Electrophoresis and Immunoblotting
Proteins were separated in 5, 7.5, or 12% polyacrylamide
(acrylamide from National Diagnostics, Atlanta, GA) gels
containing sodium dodecyl sulfate (SDS) according to
Laemmli (17) and transferred to nitrocellulose (Bio-Rad,
Hercules, CA) in 25 mM Tris, 192 mM glycine, and 20%
methanol. After transfer, the membrane was blocked in
4% milk for 1 hour at room temperature. Results were
visualized with horseradish peroxidase-conjugated second-
ary antibodies (Sigma) and enhanced chemiluminescence
(Pierce).
Determination of 2-Deoxyglucose
The assay of [3H] 2-deoxyglucose was performed as
previously described (18). Before the assay, fully differen-
tiated 3T3-L1 adipocytes were serum-deprived for 2 to 4
hours. Uptake measurements were performed in triplicate
under conditions where hexose uptake was linear, and the
results were corrected for non-specific uptake and absorp-
tion determined by [3H] 2-deoxyglucose uptake in the pres-
ence of 5 M cytochalasin B (Sigma). Non-specific uptake
and absorption was always 10% of the total uptake.
Results
The Regulation of SOCS-3 mRNA and Protein by GH
and INS
Whole-cell extracts and total RNA were isolated from
fully differentiated 3T3-L1 adipocytes that were treated for
various times with either GH or INS. As shown in Figure
1A, GH treatment resulted in the induction of SOCS-3
protein. Also, the presence of SOCS-3 protein correlated
with the loss of STAT5 tyrosine phosphorylation. INS treat-
ment did not result in the induction of SOCS-3 protein.
However, the results in Figure 1B clearly indicate that INS
treatment did result in a detectable increase in SOCS-3
mRNA. INS-treated cells showed increased levels of
SOCS-3 mRNA at 30 minutes and 1 hour, which gradually
decreased over 8 hours. Compared with INS, GH was a
much more potent inducer of SOCS-3 mRNA. The levels
of SOCS-3 mRNA levels were increased at 30 minutes and
1 hour but to a much higher degree than resulted from the
INS treatment. Interestingly, the SOCS-3 mRNA disap-
peared at a quicker rate after GH treatment. These studies
are consistent with our other studies that have shown that
doses of INS ranging from 0.33 nM to 1 M do not induce
STAT5 phosphorylation in 3T3-L1 adipocytes or in epidid-
ymal fat pads of mice that had intraperitoneal injections of
INS (19). The efficacy of the INS in this experiment was
also confirmed by the activation of ERKs 1 and 2 (data not
shown). In addition to having equivalent ethidium bromide
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staining of the RNA gel, we also examined the expression of
aP2 mRNA and did not observe any changes in expression
levels (data not shown).
Inhibition of MAPK Does Not Inhibit the GH-Induced
Activation of STAT5 or SOCS-3
Whole-cell extracts and total RNA were isolated from
fully differentiated 3T3-L1 adipocytes that were treated for
various times with either GH in the presence of the mitogen-
activated protein kinase kinase (MEK) inhibitor, U0126, or
cycloheximide (CH). As shown in Figure 2, the presence of
U0126 did not substantially effect GH-induced STAT5
phosphorylation. The efficacy of a MEK inhibitor is shown
by immunoblotting with the active MAPK (ERKs 1 and 2)
antibody, and the even loading of protein is demonstrated
with the examination of MAPK. An analysis of SOCS-3
mRNA from this experiment clearly demonstrates that CH
treatment results in a significant increase in SOCS-3
mRNA, whereas the MEK inhibitor resulted in a slight
decrease in SOCS-3 mRNA in the presence of GH. In
addition to having equivalent ethidium bromide staining of
the RNA gels, we also examined the expression of aP2
mRNA and did not observe any changes in expression
levels (data not shown).
GH Pretreatment Inhibits GH-Induced STAT5
Phosphorylation in a Manner That Is Independent of
New Protein Synthesis or Active MAPK
Whole-cell extracts were isolated from fully differenti-
ated 3T3-L1 adipocytes that were treated for various times
with GH in the presence or absence of a GH pretreatment
for the times indicated in Figure 3A. As previously shown,
acute GH treatment (15 minutes) resulted in a robust ty-
rosine phosphorylation of STAT5 proteins. This stimulation
of STAT5 was inhibited with a GH pretreatment of 2, 8, or
18 hours. Moreover, the inhibition of MAPK, by using
U0126, did not affect the ability of GH pretreatment to
inhibit STAT5 phosphorylation (Figure 3C). The results in
Figure 3B demonstrate that the presence of CH did not
affect the ability of a GH pretreatment to inhibit STAT5
phosphorylation. The expression of PPAR, a labile pro-
tein, is shown to demonstrate the efficacy of the CH treat-
ment.
Lack of Cross-Talk between GH and INS
Fully differentiated 3T3-L1 adipocytes were treated for
15 minutes with either GH or INS after the different pre-
treatment times indicated at the top of Figure 4. The cells
were homogenized and fractionated into nuclear and cyto-
Figure 1: The induction of SOCS-3 protein and mRNA after treatment with either GH or INS. (A) Whole-cell extracts were isolated from
fully differentiated 3T3-L1 adipocytes that were treated with either 125 ng/mL GH or 50 nM INS for the times indicated at the top of the
figure. One hundred micrograms of each extract was separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot
analysis. Samples were processed, and results were visualized as described in the legend. (B) Total RNA was isolated after GH or INS
treatment. Fifteen micrograms of total RNA was electrophoresed, transferred to nylon, and subjected to Northern blot analysis. This is a
representative experiment independently performed two times.
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solic extracts. The extracts were then separated by SDS-
polyacrylamide gel electrophoresis (PAGE), and results
were visualized by Western blot analysis. We observed
that acute GH treatment resulted in STAT5 phosphorylation
and nuclear translocation in adipocytes that were not GH
pretreated and in cells that were pretreated with INS for 3 or
18 hours. In addition, the results demonstrate that the acute
activation of MAPK by INS is only attenuated by INS
pretreatments but not by GH pretreatments. The results
in Figure 4 also demonstrate that GH pretreatment can
inhibit acute GH activation of MAPK and STAT5 but did
not affect acute INS activation of MAPK.
GH Pretreatment Does Not Inhibit INS-Sensitive
Glucose Uptake
Fully differentiated 3T3-L1 adipocytes were treated for
7 minutes with 50 nM INS after a 2-hour pretreatment with
GH. As shown in Table 1, acute INS stimulation resulted in
a 4.8-fold increase in glucose uptake over basal levels. After
a 2-hour pretreatment with GH, acute INS stimulation re-
sulted in a 4.4-fold increase of glucose uptake. The presence
of SOCS-3 in these conditions was confirmed by Western
blot analysis (data not shown) but was identical to the time
course of SOCS-3 protein induction shown in Figure 2.
These results demonstrate that a 2-hour pretreatment of GH
is insufficient to inhibit the effects of acute INS treatment
on glucose uptake.
Discussion
The novel observations in this study include a direct
comparison of the effects of GH and INS on STAT5 acti-
vation and the induction of SOCS-3 in 3T3-L1 adipocytes.
These results indicate that GH, but not INS, can activate
STAT5 proteins and support our recent in vivo observations
(19). However, both INS and GH can cause an induction of
SOCS-3 mRNA. Interestingly, only GH treatment resulted
in a robust increase in SOCS-3 protein. This study also
demonstrates that INS- or GH-induced SOCS-3 expression
is insufficient to attenuate GH activation of STAT5 in fat
cells, and the induction of SOCS-3 mRNA is independent of
active ERKs 1 and 2. Moreover, we have demonstrated that
GH-induced SOCS-3 expression cannot attenuate INS acti-
vation of glucose uptake or the activation of ERKs 1 and 2.
The results of our study conflict with reports that suggest
that INS is a potent inducer of STAT5B (4–6,20). Our
results also do not support recent studies that suggest that
SOCS-3 inhibits INS action (7,11). However, we have only
examined the INS activation of glucose uptake and ERKs 1
Figure 2: The GH induction of SOCS-3 mRNA is unaffected by the inhibition of MAPK activity and enhanced in the presence of CH.
Whole-cell extracts and total RNA were isolated from fully differentiated 3T3-L1 adipocytes that were treated with GH (125 ng/mL) for
the times indicated. After a 40-minute pretreatment with either 5  CH or 5 m of the MEK inhibitor (U0126) cells were harvested
at various time-points indicated in the figure. One hundred micrograms of each whole-cell extract was separated by SDS-PAGE, transferred
to nitrocellulose, and subjected to Western blot analysis. To examine SOCS-3 mRNA, 15 g of total RNA was electrophoresed, transferred
to nylon, and subjected to Northern blot analysis. This was a representative experiment independently performed three times.
GH and INS Regulation of STAT5 and SOCS-3, Story and Stephens
OBESITY Vol. 14 No. 8 August 2006 1307
Figure 3: The ability of GH pretreatment to inhibit acute GH-induced STAT5 phosphorylation is independent of new protein synthesis or
active MAPK. (A) Fully differentiated 3T3-L1 adipocytes were treated for 15 minutes with 125 ng/mL GH in the presence or absence of
a GH pretreatment for 2, 8, or 18 hours. (B) Fully differentiated 3T3-L1 adipocytes were treated for 15 minutes with GH after a 3-hour GH
pretreatment in the presence or absence of 5  CH. (C) Fully differentiated 3T3-L1 adipocytes were treated for 15 minutes with GH after
a 3-hour GH pretreatment in the presence or absence of 5 m U0126 (U2). For each part of the figure, whole-cell extracts were separated
by SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis. This is a representative experiment independently
performed three times.
Figure 4: GH induction of STAT5 activation is inhibited by GH pretreatment but not by INS pretreatment. Cytosolic and nuclear extracts
were prepared from fully differentiated 3T3-L1 adipocytes. Cells were untreated () or treated for 15 minutes with 50 nM INS (I) or 125
ng/mL GH (G). Some cells were pretreated with INS or GH for 3 and 18 hours. For each panel, 100 g of each extract was separated by
SDS-PAGE, transferred to nitrocellulose, and subjected to Western blot analysis. This is a representative experiment independently
performed four times.
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and 2 activation. It is possible that SOCS-3 can inhibit the
function of INS-activated proteins that are not associated
with glucose uptake or MAPK activation in our system.
Another study has shown that SOCS-3 plays a role in the
ubiquitin-mediated degradation of IRS proteins (21). Hence,
several groups have shown that high levels of SOCS-3
expression can inhibit INS signaling. However, all of the
studies demonstrating SOCS-3 inhibition of GH or INS
signaling were performed with ectopic overexpression of
SOCS-3, and we hypothesize that this inhibition may not
occur under physiological conditions. Although SOCS-3
has been shown to inhibit the ability of INS to phosphory-
late IRS-1 (7), and SOCS proteins can mediate the degra-
dation of IRS proteins (21), a physiological endpoint (i.e.,
glucose uptake) of these effects has not been demonstrated,
and we have shown that IRS-1 degradation is independent
of SOCS-3 expression in various conditions in adipocytes
(22). We hypothesize that our results are distinct from other
studies because we have analyzed an INS-sensitive cell
without overexpressing or knocking down any proteins that
can result in altering the levels and/or activities of other
proteins.
It is largely accepted that SOCS proteins form part of a
classic negative feedback circuit. SOCS family members
modulate signaling by several mechanisms including the
inactivation of the JAKs, blocking access of the STATs to
receptor binding sites, and ubiquitination of signaling pro-
teins and their subsequent targeting to the proteasome (3).
Gene targeting experiments have been used to generate
mice lacking socs1, socs2, or socs3 to elucidate the physi-
ological function of these SOCS family members. The anal-
ysis of socs1(/) mice has revealed that SOCS-1 plays a
key role in the negative regulation of interferon- signaling
and in T cell differentiation (23). Socs2(/) mice are
substantially larger (30%) than wild-type mice and sug-
gest that SOCS-2 is a critical regulator of postnatal growth
(24). Finally, the study of embryos lacking socs3 has re-
vealed that SOCS-3 is an important regulator of placental
development and the absence of this protein results in
embryonic lethality (25,26). The biological role of other
SOCS proteins remains to be determined.
There is a large body of literature on how GH counteracts
INS action on lipid and glucose metabolism and how INS
signaling is modulated in states of excess GH and GH
deficiency. For example, patients with pituitary tumors that
produce excess GH are INS resistant (27,28). Also, in vivo
studies on chronic administration of GH in rats demonstrate
INS resistance with decreased INS receptor and IRS-1 phos-
phorylation (29,30). Also, it is well established that GH and
INS signaling pathways use a number of the same proteins
and have the ability to influence the action of the other (31).
However, our studies on the acute actions of these signaling
pathways suggest that STAT5 is not a key mediator of INS
action and that early attenuation of GH signaling is inde-
pendent of the induction of SOCS-3. It is well established
that inhibition of GH signaling can be caused by internal-
ization of the GH receptor, a plasma membrane protein
whose internalization is mediated by the ubiquitin-protea-
some pathway (32). In fact, a recent study has demonstrated
that the ubiquitination, endocytosis, and degradation of the
GH receptor is independent of signal transduction by Janus
kinase 2 (33). Our results would also suggest that the
ubiquitination, endocytosis, and degradation of the GH re-
ceptor is independent of the induction of SOCS-3 (Figure 3)
and that the induction of SOCS-3 by GH is insufficient to
inhibit INS-induced activation of ERKs 1 and 2 or signaling
proteins that are activated for INS-sensitive glucose uptake
(Figure 4; Table 1), such as INS receptor tyrosine kinase,
IRS-1, and AKT. In summary, our results are distinct from
other recent studies, and our findings demonstrate that the
induction of SOCS-3 is not required for the initial attenua-
tion of GH or INS signaling, and STAT5 is not activated by
INS in 3T3-L1 adipocytes. Our results are supported by a
study in rats demonstrating that GH treatment affects
GLUT1 and GLUT 4 expression, but despite these alter-
ations, the abundance of both transporters in the plasma
membrane fraction of adipocytes incubated with 0.1 U
INS/mL was not diminished by GH (29). Moreover, an
independent study has revealed that SOCS-3 expression in
human skeletal muscle in vivo is not related to INS resis-
tance (34). Also, a recent study has also observed that
common polymorphisms in SOCS-3 are not associated with
Table 1. Glucose transport activity
Treatment
Basal (pM/min
per milligram of protein)
Insulin-stimulated
(pM/min
per milligram of protein)
Fold stimulation
(pM/min
per milligram of protein)
None 75  8 360  28 4.8
2 hours growth hormone 80  9 348  20 4.4
2-Deoxyglucose was determined at 23°C and corrected for nonspecific diffusion. The mean  standard deviation (n  6) is shown.
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INS sensitivity (35). The functional interactions between
GH and INS signaling pathways are complex and poorly
understood, particularly in adipocytes. Future studies will
examine the role of SOCS-3 with chronic pretreatments of
INS and GH and focus on studying the other functions of
SOCS proteins, such as their role in ubiquitin-proteasome-
mediated degradation.
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